Scope and patent landscape for US Drug Patent 8,017,150: mucosally-adhesive water-soluble films for opioid analgesics using polyethylene oxide and hydrophilic cellulosic polymers
United States Patent 8,017,150 is directed to a mucosally-adhesive, water-soluble oral film for delivery of an opioid analgesic active, using a polymer system that is overwhelmingly polyethylene oxide (PEO) with a capped fraction of a hydrophilic cellulosic polymer. The claim set defines (i) the polymer blend ratio and (ii) specific molecular-weight bands for low- and high-molecular-weight PEO fractions, plus (iii) optional commercial-type formulation attributes (viscosity, thickness, sweeteners, flavors, buffers, and additional actives). The scope is concentrated on formulation-specific constraints, not on the identity of the opioid, and it is therefore most relevant as a claim barrier to generic/authorized substitutes that preserve the same PEO/cellulosic composition architecture and similar physical film parameters.
What is US Patent 8,017,150 claiming and what is the core invention?
Short answer: It claims a mucosally-adhesive water-soluble film containing an opioid analgesic plus a specific PEO + hydrophilic cellulosic polymer system, with defined ratio limits and defined PEO molecular-weight bands.
Claim 1: polymer composition and PEO molecular-weight architecture
Claim 1 recites a film product comprising:
- An analgesic opiate pharmaceutical active (opioid active, generically defined)
- At least one water-soluble polymer component consisting of:
- PEO + hydrophilic cellulosic polymer
- Polymer blend fraction rule: PEO is >75% and up to 25% is the hydrophilic cellulosic polymer, i.e., the cellulosic polymer is capped at 25% of the polymer component.
- PEO fractionation by molecular weight:
- “Low molecular weight polyethylene oxides” with MW 100,000 to 300,000
- “Higher molecular weight polyethylene oxides” with MW 600,000 to 900,000
- Low-MW PEO loading rule: The low-MW PEO is about 60% or more of the polymer component.
Practical claim meaning: For infringement analysis, the dispositive question is whether the accused film uses a PEO/cellulosic system where:
- PEO fraction is dominant (cellulosic ≤25%),
- PEO contains both low- and high-MW fractions in the specified MW windows, and
- low-MW fraction is about 60%+ within the polymer component.
Dependent claims 2-3: physical film parameters tied to viscosity and thickness
- Claim 2: film viscosity ~1,000 cP to ~40,000 cP
- Claim 3: film thickness ~3 mils to ~6 mils
These parameters are typical formulation guardrails that reduce design-around freedom by requiring a formulation whose bulk rheology and resulting film gauge land within the recited windows.
Dependent claims 4-9: optional add-ins (additional actives, sweeteners, flavors, buffers)
- Claim 4: additional pharmaceutical active
- Claim 5: one or more sweeteners
- Claims 6-7: sweeteners include:
- hydrogenated starch hydrolysate
- potassium salt of 3,6-dihydro-6-methyl-1-1-1,2,3-oxathiazin-4-one-2,2-dioxide
- Claim 8: flavors
- Claim 9: buffers
These claims broaden coverage to finished products incorporating common film excipients, including two sweetener embodiments that read as specific preferred systems.
What does claim 10 add or change versus claim 1?
Claim 10 restates the film structure with the same overall concept but changes the polymer ratio constraint.
Key difference: a broader upper bound on cellulosic fraction (up to about 4:1)
Claim 10 requires:
- PEO + hydrophilic cellulosic polymer
- Cellulosic ratio: hydrophilic cellulosic polymer in a ratio of up to about 4:1 with PEO
Interpreting the wording in a formulation context:
- “ratio of up to about 4:1 with the polyethylene oxide” indicates the cellulosic polymer is at most about one-quarter of the PEO amount, consistent with allowing cellulosic fractions near or below 20-25% of polymer component depending on how “ratio” is interpreted relative to component definitions.
Claim 10 still keeps:
- Same PEO molecular-weight windows (100,000-300,000 and 600,000-900,000)
- Same low-MW loading rule (low-MW PEO about 60% or more)
- Dependent claims (11-18) largely mirror claims 2-9: viscosity range, thickness range, additional actives, sweeteners, flavors, and buffers.
Implication: Claim 10 likely provides an alternate way to satisfy the polymer blend constraints with an expressly different ratio articulation, strengthening enforceability against polymers that are close to—but structured differently than—the “>75% PEO / up to 25% cellulosic” formulation in claim 1.
Where are the claim boundaries for design-around?
US 8,017,150 is formulation-parameter heavy. The tightest boundaries are:
- Polymer identity (PEO + hydrophilic cellulosic)
- Polymer fraction limits (PEO dominates; cellulosic capped)
- PEO molecular weight distribution (two MW bands)
- Low-MW PEO loading (≥~60%)
- Film viscosity and thickness ranges (only required for dependent coverage)
Design-around levers likely evaluated in validity/infringement disputes
- Changing polymer blend ratio: moving cellulosic fraction above the capped level or changing the PEO dominance so that PEO is not >75% of the polymer component (claim 1) and/or not within the “up to about 4:1” framing (claim 10).
- Changing PEO molecular weight distribution: using only one MW distribution, or shifting low-MW out of 100,000-300,000, or shifting high-MW out of 600,000-900,000.
- Changing low-MW proportion: reducing low-MW below “about 60% or more.”
- Changing physical film characteristics: landing viscosity outside 1,000-40,000 cP and/or thickness outside 3-6 mils (to avoid dependent claim coverage, though independent claim 1/10 may still be implicated if polymer architecture remains).
- Recasting the sweetener/flavor/buffer system: swapping out the specific sweeteners named in dependent claims 6-7 to avoid those narrower embodiments (while still potentially infringing broader claims that do not require those sweeteners).
How strong is the patent estate around this concept (and how do you map related IP)?
You provided only the claim text. A complete patent landscape requires bibliographic data (publication numbers, priority date, assignees, prosecution history, and citations) and cannot be reliably constructed from claim text alone. Under the constraints of this task, no definitive landscape assertions about related patents, continuations, family members, or litigation can be made.
What can be mapped from the claim structure itself: the claims target a narrow but commercially meaningful formulation “space” that is likely reused across product lines of oral mucosally-adhesive films and drug-in-film technologies. If multiple products exist in the same family (opioid film plus similar polymer matrix), related patents may concentrate on one or more of:
- PEO/cellulosic blend ratios and PEO MW fractionation
- Viscosity/thickness ranges for film manufacturability
- Specific sweeteners and excipient packages that affect adhesion and taste
- Methods of making such films or controlling molecular-weight distributions (if those were pursued separately)
However, without identifying the patent family, assignee, and citation set from the actual record, no “how many patents cover” count or expiration timeline can be generated without risking incorrect business conclusions.
What patents protect the same product concept across opioid films versus other mucosal films?
Short answer: This patent protects opioid-containing mucosally-adhesive water-soluble films that use a specific PEO + hydrophilic cellulosic polymer system with defined MW fractions and dominance of PEO.
Scope anchored on “opioid analgesic active”
The opioid is described broadly as “an analgesic opiate pharmaceutical active.” That supports coverage across multiple opioid actives if incorporated into the claimed film matrix, assuming the accused product’s polymer system matches the claimed PEO/cellulosic constraints.
Scope anchored on polymer system, not drug substance
Even if the opioid changes, the polymer architecture is still the gating limitation. For competitive intelligence, the most actionable infringement risk typically comes from competitors copying the same polymer blending strategy rather than from swapping the opioid.
How does the polymer MW definition affect infringement and claim construction?
This patent’s novelty is framed through specific PEO molecular-weight windows and low-MW proportion.
Potential infringement evidence needed (conceptually)
In disputes, polymer MW distribution is the key technical fact:
- Gel permeation chromatography (GPC) or similar methods to quantify molecular-weight distribution of PEO fractions
- Quantification of the low-MW fraction (100,000-300,000) as a proportion of total polymer component
- Confirming the fraction of hydrophilic cellulosic polymer in the polymer component (for claim 1) and the ratio framing (for claim 10)
What “about” signals for enforcement
The claims use “about” in several ranges:
- low-MW is “about 60% or more”
- viscosity and thickness have “about” boundaries
This typically widens interpretive flexibility, so a competitor trying to avoid infringement by inching the values near boundaries may not succeed if their formulation still falls within the practical meaning of “about” ranges.
How do the dependent claims expand coverage to real-world formulations?
The dependent claims (4-9, 13-18) broaden claim coverage to typical finished-product variations.
What is explicitly covered
- Additional pharmaceutical actives (claim 4 / 13)
- Sweeteners, including specific named sweeteners (claim 5-7 / 14-16)
- Flavors (claim 8 / 17)
- Buffers (claim 9 / 18)
What is not specified in the claim text you provided
- Exact opioid identity
- Exact cellulosic polymer species (only “hydrophilic cellulosic polymer”)
- Exact method steps for film manufacture
So, the patent is not limited to a single opioid identity in the claim language you provided, but is limited to the polymer blend concept as stated.
When does US 8,017,150 lose exclusivity?
No expiration/exclusivity date can be stated from claim text alone. Patent term depends on:
- filing and priority dates,
- whether it is subject to adjustments,
- whether it has patent-term extension,
- and the status of any terminal disclaimers and related family members.
Key claim map (for fast infringement screening)
| Claim |
Core requirement |
Tightest constraints |
Add-on coverage |
| 1 |
Opioid mucosally-adhesive water-soluble film |
PEO >75% and cellulosic ≤25% of polymer component; PEO has low MW 100k-300k and high MW 600k-900k; low MW PEO is about 60%+ |
viscosity/thickness/sweeteners/flavors/buffers only via dependents |
| 2 |
Claim 1 + viscosity window |
~1,000-40,000 cP |
none |
| 3 |
Claim 1 + thickness window |
~3-6 mils |
none |
| 4 |
Claim 1 + additional active |
none beyond Claim 1 |
yes, additional actives |
| 5-7 |
Claim 1 + sweeteners |
includes named sweeteners (hydrogenated starch hydrolysate; potassium salt of oxathiazinone dioxide) |
yes |
| 8 |
Claim 1 + flavors |
none beyond Claim 1 |
yes |
| 9 |
Claim 1 + buffers |
none beyond Claim 1 |
yes |
| 10 |
Claim 1-like matrix with alternate ratio language |
hydrophilic cellulosic polymer up to about 4:1 with PEO; same PEO MW bands and low MW ≥~60% |
none |
| 11-18 |
Dependents mirroring 2-9 |
viscosity and thickness; then additional actives, sweeteners, flavors, buffers |
yes |
Key Takeaways
- US 8,017,150 is a formulation patent for mucosally-adhesive water-soluble opioid films built around a dominant PEO system mixed with a capped hydrophilic cellulosic polymer.
- The strongest claim hooks are the PEO molecular-weight banding (100k-300k low MW and 600k-900k high MW) plus the low-MW PEO proportion (about 60%+), coupled with a PEO-dominant blend rule (claim 1) or an alternate ratio rule (claim 10).
- Dependent claims add practical manufacturing and product-definition constraints via viscosity (1,000-40,000 cP) and thickness (3-6 mils), and they extend coverage to common excipient packages including named sweeteners.
FAQs
-
If a generic uses a different opioid but the same PEO/cellulose polymer system, is it still exposed under US 8,017,150?
The claim language covers an “analgesic opiate pharmaceutical active,” so opioid identity is not the limiting factor; the polymer system constraints are.
-
How can a competitor avoid dependent claim coverage for viscosity and thickness?
By producing films whose measured viscosity and thickness fall outside the recited “about” ranges, while still assessing independent claim exposure for polymer architecture.
-
Does swapping the sweetener avoid infringement of the sweetener-dependent claims?
Replacing sweeteners named in the dependent claims (e.g., hydrogenated starch hydrolysate and the specified potassium salt) can avoid those narrower embodiments, but it does not remove exposure under claims that do not require those sweeteners.
-
Which part of the polymer system is most likely to be litigated: the blend ratio or the PEO molecular-weight distribution?
Both can be litigated, but the claim’s molecular-weight banding and low-MW proportion are usually the most technically diagnostic features.
-
Are these claims limited to a specific hydrophilic cellulosic polymer type?
The provided claim text does not specify a particular cellulosic polymer identity, only “hydrophilic cellulosic polymer,” so infringement analysis depends on whether the accused polymer qualifies within that functional category.
References
- United States Patent 8,017,150 (claim text provided in prompt).
